The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|March 22, 2019
Pharmapack Europe Event Organizers Predict Sizeable Sector Growth Potential
Author(s)Pharmaceutical Technology Editors
The organizers of Pharmapack Europe have revealed their prediction that the drug delivery and healthcare packaging industry will experience significant growth during 2019.
Advertisement
In a March 19, 2019 press statement, the organizers of Pharmapack Europe have revealed their prediction that the drug delivery and healthcare packaging industry will experience significant growth during 2019, mirroring the success of this year’s Pharmapack event in Paris.
With 405 exhibitors and nearly 5500 attendees, from 75 countries, the latest edition of Pharmapack Europe, which took place on Feb. 6–7, 2019, was reported as being one of the most successful so far. Additionally, expansions in content and awards were also witnessed during the 2019 event, where ‘patient-centricity’ was highlighted as the central theme.
“This year’s event demonstrated what an exciting time it is for drug delivery and packaging,” commented Silvia Forroova, brand director at Pharmapack Europe, in the statement. “I anticipate many of the innovations seen on the show floor delivering improvements in patient care over the next few years-in particular those across patient friendly and sustainable solutions.”
During the show, the conference agenda, which was delivered by industry speakers, explored current pharma packaging and drug delivery trends and analyzed regulatory changes in the European Union and United States markets. Major topics discussed at the event included patient adherence, biologicals and biosimilars, challenges in usability, and sustainability.
“The conference agenda showed the depth and breadth of new developments and 2019 looks set to bring a golden age of patient focused developments and innovations from smart packaging and connected devices to autoinjectors. Our agenda also highlighted the importance of partnering to bring newer innovations to market, meeting new contacts who can help scale-up promising technologies beyond clinical development and into commercial supply,” added Forroova. “This is why an event like Pharmapack remains so crucial to industry innovation moving forwards; it’s about meeting contacts, exchanging ideas, and learning vital new skills to help further the industry so we can deliver new solutions for patients globally.”
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement